ISCHEMIA-EXTEND (Extended Follow-up)

Launched by NYU LANGONE HEALTH · May 18, 2021

Keywords

ClinConnect Summary

The ISCHEMIA-EXTEND trial is a long-term study looking at the effects of two different treatment approaches for patients with stable ischemic heart disease, which is a condition where the heart doesn't get enough blood and oxygen. In the original ISCHEMIA study, over 5,000 participants were randomly assigned to either receive more immediate procedures such as heart catheterization and possible surgery, or to start with medication management alone. The goal of the follow-up study is to see how these two strategies affect overall health and survival over a median period of 10 years.

To be eligible for this follow-up, participants need to have been alive at the end of the initial study and must not have withdrawn their consent to participate. During this follow-up phase, researchers will assess the long-term outcomes related to heart health and overall death rates, including whether one treatment is better than the other over time. It's important for patients and their families to know that this trial aims to provide clearer insights into the best treatment options for managing heart disease, which can ultimately help guide future patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Alive at the end of the initial follow-up period for ISCHEMIA
• Exclusion Criteria:
• • Participants who withdrew consent during initial trial phase
• • Participants who declined participation in long-term follow-up